---
title: "Vietnam Medipharm Expo 2025 returns to Hà Nội"
description: "The Vietnam Medipharm Expo 2025 will take place in Hà Nội from May 8-11, featuring over 300 exhibitors from 30 countries. Organized by VIMEDIMEX VN and VIETFAIR, the event aims to showcase products, f"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/236520815.md"
published_at: "2025-04-18T04:56:21.000Z"
---

# Vietnam Medipharm Expo 2025 returns to Hà Nội

> The Vietnam Medipharm Expo 2025 will take place in Hà Nội from May 8-11, featuring over 300 exhibitors from 30 countries. Organized by VIMEDIMEX VN and VIETFAIR, the event aims to showcase products, facilitate technology transfer, and explore investment opportunities. Discussions will cover topics like Japanese preventive medicine and pharmaceutical regulations. The global medical device market is expected to grow from $637.04 billion in 2024 to $893.07 billion by 2029, while Vietnam's medical device market is valued at $1.677 million with a CAGR of 10.2%.

Visitors at the Vietnam Medi-Pharm 2024. — Photo courtesy of the event's organisers

HÀ NỘI — The 32nd edition of the Vietnam International Medical and Pharmaceutical Exhibition (Vietnam Medipharm Expo 2025) is scheduled to take place in the capital from May 8-11 at the International Exhibition Centre in Hà Nội.

The event will host over 300 exhibitors from 30 countries and regions, including the United States, India, Germany, the Czech Republic, Russia, mainland China, South Korea, Japan, Malaysia, Taiwan and Hong Kong.

Organised annually by the Vietnam Medical Import-Export JSC (VIMEDIMEX VN) and Vietnam Advertisement and Fair Exhibition JSC (VIETFAIR), the exhibition provides a crucial platform for businesses and organisations to showcase their products, exchange industry expertise, explore investment opportunities, form joint ventures and facilitate technology transfer to enhance production efficiency.

The event will also feature discussions on a range of topics, including advances in Japanese preventive medicine, pharmaceutical law, along with medical equipment and supplies regulations, organisers said.

The global medical device market is projected to grow significantly, from US$637.04 billion in 2024 to $893.07 billion by 2029, equivalent of an annual growth rate of 6.99 per cent.

In Việt Nam, the medical device market is also robust, valued at $1.677 million and experiencing a compound annual growth rate (CAGR) of 10.2 per cent. This growth is fuelled by factors such as an ageing population, increasing standards of living and favourable policies aimed at attracting foreign investment and promoting technology transfer. — VNS

### Related Stocks

- [EXPO.US - Exponent](https://longbridge.com/en/quote/EXPO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Exponent Inc. stellt neue Investorenpräsentation mit Fokus auf technische Exzellenz und multidisziplinäre Lösungen vor | Exponent Inc. has released a new investor presentation focusing on technical excellence and multidisciplinary solutions. | [Link](https://longbridge.com/en/news/275047333.md) |
| Exponent's Q4 revenue rises 7.8%, beats expectations | Exponent's Q4 revenue rose 7.8%, surpassing analyst expectations, with net income also increasing. The company announced | [Link](https://longbridge.com/en/news/275032005.md) |
| Huatai Securities Reaffirms Their Buy Rating on Hong Kong Exchanges & Clearing (HKXCF) | In a report released yesterday, from Huatai Securities maintained a Buy rating on Hong Kong Exchanges & Clearing, with a | [Link](https://longbridge.com/en/news/275995421.md) |
| Uber Enters 7 New European Markets In Food Delivery Push- FT | UBER ENTERS 7 NEW EUROPEAN MARKETS IN FOOD DELIVERY PUSH- FT | [Link](https://longbridge.com/en/news/275995937.md) |
| Ibn Al Haytham Hospital FY Income 301,281 Dinars | Ibn Al Haytham Hospital Company PSC (IBNH.AM):IBN AL HAYTHAM HOSPITAL FY NET INCOME AFTER TAX 301,281 DINARSIBN AL HAYTH | [Link](https://longbridge.com/en/news/275996849.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
